Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
A phase 1/2 trial of Antibody-Drug Conjugate in advanced solid tumours, run by MBrace Therapeutics, now recruiting.
Overview
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT06014658 by MBrace Therapeutics, with 130 participants planned, started 2023-11-07 and due to reach its primary completion in 2026-07. Interventions recorded: Antibody-Drug Conjugate.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Shares MBrace Therapeutics and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.